Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.69 |
| ▸ | PAK1 | Q13153 | 11/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700483 | 1.00 | PIM1 (0.69) | PIM1PAK1PIM2MAPK1FLT3 | |
| SCHEMBL10091712 | 0.92 | PIM1 (0.67) | PIM1PAK1PIM2FLT3PIM3 | |
| SCHEMBL700175 | 0.86 | PIM1 (0.63) | PIM1PAK1PIM2FLT3PIM3 | |
| SCHEMBL10091870 | 0.86 | PIM1 (0.63) | PIM1PAK1PIM2FLT3PIM3 | |
| SCHEMBL700174 | 0.86 | PIM1 (0.63) | PIM1PAK1PIM2FLT3PIM3 | |
| SCHEMBL10091711 | 0.83 | PIM1 (0.59) | PIM1PIM2FLT3PIM3 | |
| SCHEMBL699128 | 0.82 | PIM1 (1.00) | PIM1PIM2FLT3PIM3 | |
| SCHEMBL699129 | 0.82 | PIM1 (1.00) | PIM1PIM2FLT3PIM3 | |
| SCHEMBL10091713 | 0.81 | PIM1 (0.60) | PIM1PIM2FLT3PIM3 | |
| SCHEMBL10091710 | 0.77 | PIM1 (0.77) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PAK1 385/4885PIM2 3/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PAK1 385/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.